Prof Wolfgang Janni speaks to ecancer in an online interview for the virtual SABCS 2020 meeting on a study that looked at using circulating tumour cell dynamics as a predictor for treatment response and prognosis in metastatic breast cancer patients.
He explains that peer record publications were screened for data on repeated CTC assessments and overall 4079 patient's records were studied.
Prof Janni reports that after splitting the patients into sub groups patients who were persistently CTC negative had a much longer overall survival compared to patients who were persistently CTC positive.